YAYannick Arlot-Bonnemains

Yannick Arlot-Bonnemains

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yannick Arlot-Bonnemains has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Franck Chesnel

    CNRS UMR6290, Université Rennes 1, SFR-UMSCNRS 3480-INSERM 018, Rennes, France

    5 shared publications
  • Xavier Le Goff

    IGDR (Institut de ge ´ne ´tique et de ´veloppement de Rennes)-UMR 6290 Univ Rennes CNRS France

    5 shared publications
  • Anne Couturier

    CNRS UMR6290, Université Rennes 1, SFR-UMSCNRS 3480-INSERM 018, Rennes, France

    4 shared publications
  • Claude Prigent

    4 shared publications
  • Adrien Alusse

    CNRS UMR6290, Université Rennes 1, SFR-UMSCNRS 3480-INSERM 018, Rennes, France

    2 shared publications
  • Andrea Klotzbucher

    Institut für Molekulare Onkologie, KTB-Klinik für Tumorbiologie. Breisacher Strasse 117, 79106 Freiburg. Germany.Groupe Cycle Cellulaire, UMR6061 Génétique et Développement, CNRS-Université de Rennes 1. IFR 97 Génomique Fonctionnelle et Santé, Faculté de Médecine, 2 avenue du Pr Léon Bernard, CS 34317, 35043 Rennes Cedex. France

    2 shared publications

Latest Publications

  • Open Access

    Aurora A Kinase Begins to Localize to the Centrosome in the S-phase of the Cell Cycle in the XL2 Cell Line

    by Rustem Uzbekov, Svetlana Uzbekova, Fedor Severin, Claude Prigent, Yannick Arlot-Bonnemains

    Background: The centrosome is one of the principal cell hubs, where numerous proteins important for intracellular regulatory processes are concentrated. One of them, serine-threonine kinase 6, alias Aurora A, is involved in centrosome duplication and mitotic spindle formation and maintenance. Methods: Long-term vital observations of cells, immunofluorescence analysis of protein localization, synchronization of cells at different phases of the cell cycle, Western blot analysis of protein content were used in the work. Results: In this study, we investigated the dynamics of Aurora A protein accumulation and degradation in the XL2 Xenopus cell line during its 28-hour cell cycle. Using Western blot and immunofluorescence analyses, we demonstrated that Aurora A disappeared from the centrosome within one hour following mitosis and was not redistributed to other cell compartments. Using double Aurora A/Bromodeoxyuridine immunofluorescence labeling of the cells with precisely determined cell cycle stages, we observed that Aurora A reappeared in the centrosome during the S-phase, which was earlier than reported for all other known proteins with mitosis-specific centrosomal localization. Moreover, Aurora A accumulation in the centrosomal region and centrosome separation were asynchronous in the sister cells. Conclusions: The reported data allowed us to hypothesize that Aurora A is one of the primary links in coordinating centrosome separation and constructing the mitotic spindle.


  • Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel–Lindau gene in the ccRCC

    by Franck Chesnel, Emmanuelle Jullion, Olivier Delalande, Anne Couturier, Adrien Alusse, Xavier Le Goff, Marion Lenglet, Betty Gardie, Caroline Abadie, Yannick Arlot-Bonnemains

    Background The von Hippel–Lindau disease is an autosomal dominant syndrome associated with tumour formation in various tissues, such as retina, central nervous system, kidney, and adrenal glands. VHL gene deletion or mutations support the development of various cancers. Unclassified VHL variants also referred as “of unknown significance” result from gene mutations that have an unknown or unclear effect on protein functions. The P81S mutation has been linked to low penetrance Type 1 disease but its pathogenic function was not clearly determined. Methods We established a stable cell line expressing the pVHL213 (c.241C>T, P81S) mutant. Using biochemical and physiological approaches, we herein analysed pVHL folding, stability and function in the context of this VHL single missense mutation. Results The P81S mutation mostly affects the non-canonical function of the pVHL protein. The cells expressing the pVHL213P81S acquire invasive properties in relation with modified architecture network. Conclusion We demonstrated the pathogenic role of this mutation in tumour development in vhl patients and confirm a medical follow up of family carrying the c.241C>T, P81S.


  • Open Access

    The prefoldin complex stabilizes the von Hippel-Lindau protein against aggregation and degradation

    by Franck Chesnel, Anne Couturier, Adrien Alusse, Jean-Philippe Gagné, Guy G Poirier, Dominique Jean, François-Michel Boisvert, Pauline Hascoet, Luc Paillard, Yannick Arlot-Bonnemains, et al.

    Loss of von Hippel-Lindau protein pVHL function promotes VHL diseases, including sporadic and inherited clear cell Renal Cell Carcinoma (ccRCC). Mechanisms controlling pVHL function and regulation, including folding and stability, remain elusive. Here, we have identified the conserved cochaperone prefoldin complex in a screen for pVHL interactors. The prefoldin complex delivers non-native proteins to the chaperonin T-complex-protein-1-ring (TRiC) or Cytosolic Chaperonin containing TCP-1 (CCT) to assist folding of newly synthesized polypeptides. The pVHL-prefoldin interaction was confirmed in human cells and prefoldin knock-down reduced pVHL expression levels. Furthermore, when pVHL was expressed inSchizosaccharomyces pombe, all prefoldin mutants promoted its aggregation. We mapped the interaction of prefoldin with pVHL at the exon2-exon3 junction encoded region. Low levels of the PFDN3 prefoldin subunit were associated with poor survival in ccRCC patients harboring VHL mutations. Our results link the prefoldin complex with pVHL folding and this may impact VHL diseases progression.


  • Open Access

    Publisher's Note: Progesterone regulates the accumulation and the activation of Eg2 kinase in Xenopus oocytes (J. Cell Sci. 113, 1127-1138)

    by Marie Frank-Vaillant, Olivier Haccard, Catherine Thibier, René Ozon, Yannick Arlot-Bonnemains, Claude Prigent, Catherine Jessus

    Journal of Cell Science was made aware of several issues raised by readers concerning duplication of data in Fig. 6A, Fig. 10B, Fig. 7A and Fig. 8A,B in J. Cell Sci. (2000) 113, 1127-1138.After discussion with the corresponding author, Catherine Jessus, the journal referred this matter to Université Pierre et Marie Curie (UPMC, now Sorbonne Université), who investigated and cleared the authors of any wrongdoing. The UPMC committee concluded that no correction was necessary (full reports available at: http://www2.cnrs.fr/sites/communique/fichier/rapport_conclusions.pdf and http://www2.cnrs.fr/sites/communique/fichier/rapport_analyse_detaillee.pdf).The editorial policies of Journal of Cell Science state that: “Should an error appear in a published article that affects scientific meaning or author credibility but does not affect the overall results and conclusions of the paper, our policy is to publish a Correction…” and that a Retraction should be published when “…a published paper contain[s] one or more significant errors or inaccuracies that change the overall results and conclusions of the paper…”. Journal of Cell Science follows the guidelines of the Committee of Publication Ethics (COPE), whose advice on this case was: “…if the findings as described in the text are unchanged and the conclusion is unchanged, then it is entirely reasonable for the journal to issue a note, alerting readers, from now on, to the issues with the blots.” As the investigating committee at UPMC cleared the authors of wrongdoing and concluded that no Correction was necessary, the appropriate course of action – according to the advice from COPE – is to publish a Publisher's Note, which the journal has made as detailed as possible.The authors were unable to locate original data for this paper. The policy of the UPMC is that authors should retain original data for 10 years and the paper falls outside this period.The authors justify the use of the same control data in blots in Fig. 6A and Fig. 10B, and Fig. 7A and Fig. 8A,B since the conditions were exactly the same in each case. They use two alternative phrases, a precise one (‘2 hours later’) and a more global one (‘when 100% GVBD was reached’), to indicate the same time of collection of oocytes and state that: “The re-use of Cyclin B2 and Eg2 blots is fully justified as they arise from one single experiment, using the same oocytes and same conditions, from which different parts are illustrated in different figures. The same controls were re-used each time and are identical despite the slightly different wording [in the figure legends]”.Readers should also note that there are unmarked splices on some of the blots in the paper. Although such splicing is not acceptable by today's standards, it was a common practice when the paper was published, which was before the journal's policy on figure manipulation was implemented (early in 2013).Journal of Cell Science refers readers to other notices related to the UPMC investigation:doi:10.1242/jcs.166553doi:10.1242/jcs.222182doi:10.1242/jcs.222240doi:10.1242/dev.169573

  • Open Access

    The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes includingTGFB1andMMP13

    by Pauline Hascoet, Franck Chesnel, Florence Jouan, Cathy Le Goff, Anne Couturier, Eric Darrigrand, Fabrice Mahe, Nathalie Rioux-Leclercq, Xavier Le Goff, Yannick Arlot-Bonnemains

    The pVHL 172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13 The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13


  • Open Access

    Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis

    by Pauline Hascoet, Franck Chesnel, Cathy Le Goff, Xavier Le Goff, Yannick Arlot-Bonnemains

    Human tumours exhibit a variety of genetic alterations, including point mutations, translocations, gene amplifications and deletions, as well as aneuploid chromosome numbers. For carcinomas, aneuploidy is associated with poor patient outcome for a large variety of tumour types, including breast, colon and renal cell carcinoma. The Renal cell cancer (RCC) is a heterogeneous carcinoma consisting of different histologic types. The clear renal cell carcinoma (ccRCC) is the most common subtype and represents 85 % of the RCC. Central to the biology of the ccRCC is the loss of function of the Von Hippel Lindau gene but is also associated with genetic instability that could be caused by abrogation of the cell cycle mitotic spindle checkpoint and may involve the Aurora kinases, which regulate centrosome maturation. Aneuploidy can also result from the loss of cell-cell adhesion and apical-basal cell polarity that also may be regulated by the mitotic kinases (Plk1, CK2, DLCK1 and Aurora kinases). In this review, we describe the “non mitotic” unconventional functions of these kinases in renal tumourigenesis.


  • Open Access

    Integrative analysis of high-throughput RNAi screen data identifies the FER and CRKL tyrosine kinases as new regulators of the mitogenic ERK-dependent pathways in transformed cells

    by Philippe Nizard, Frédéric Ezan, Dominique Bonnier, Nolwenn Le Meur, Sophie Langouët, Georges Baffet, Yannick Arlot-Bonnemains, Nathalie Théret

    Cell proliferation is a hallmark of cancer and depends on complex signaling networks that are chiefly supported by protein kinase activities. Therapeutic strategies have been used to target specific kinases but new methods are required to identify combined targets and improve treatment. Here, we propose a small interfering RNA genetic screen and an integrative approach to identify kinase networks involved in the proliferation of cancer cells.


  • Open Access

    Overexpression of the polarity protein PAR‐3 in clear cell renal cell carcinoma is associated with poor prognosis

    by F. Dugay, X. Le Goff, N. Rioux‐Leclerq, F. Chesnel, F. Jouan, C. Henry, F. Cabillic, G. Verhoest, C. Vigneau, Y. Arlot‐Bonnemains, et al.

    The partition‐defective 3 (PAR‐3) protein is implicated in the development and maintenance of cell polarity and is associated with proteins that mediate the changes in cytoskeleton organization required for cell polarity establishment. In this work, we used two original primary cell lines (R‐180 and R‐305) derived from clear cell Renal Cell Carcinoma (ccRCC) surgical specimens of a patient with unfavorable clinical course (R‐180 cells) and a patient with favorable prognosis (R‐305 cells) to identify genetic and molecular features that may explain the survival difference of the two patients. The cytogenetic analysis of these cell lines revealed that the PARD3 gene was amplified only in the R‐180 cell line that was derived from an aggressive ccRCC. PARD3 gene amplification was associated with overexpression of the encoded protein and altered cytoskeleton organization. Consistently, PARD3 knockdown in R‐180 cells restored the cytoskeleton organization and reduced cell migration in comparison to non‐transfected cells. Immunohistochemical analysis of ccRCC samples from a cohort of 96 patients with a follow‐up of 6 years revealed that PAR‐3 overexpression was correlated with poor survival. Our results suggest that PAR‐3 has a role in the clinical aggressiveness of ccRCC, possibly by promoting cell migration.


  • Open Access

    Identification of pVHL as a Novel Substrate for Aurora-A in Clear Cell Renal Cell Carcinoma (ccRCC)

    by Benedicte Martin, Franck Chesnel, Jean-Guy Delcros, Florence Jouan, Anne Couturier, Frederic Dugay, Xavier Le Goff, Jean-Jacques Patard, Patricia Fergelot, Cecile Vigneau, et al.

    Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney cancer and is often characterized by mutations or deletions of the Von Hippel Lindau (VHL) tumour suppressor gene. Aurora gene family members are implicated in proper mitotic progression and spindle checkpoint function and play a crucial role in cancer progression. In the present study, we assessed the expression of Aurora-A in a cohort of 30 ccRCC with fully characterized VHL status (wt/wt or mut/del) and Fuhrman grade. Aurora-A transcript and protein levels were significantly increased in high Fuhrman grade tumours and in VHLwt/wt tumours. These results suggest that Aurora-A and VHL interact in the ccRCC. We demonstrated that the two proteins interact in vivo and identified the Ser72 on the sequence of VHL as the unique site phosphorylated by Aurora-A.


  • Open Access

    Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT

    by Enke Baldini, Yannick Arlot-Bonnemains, Salvatore Sorrenti, Caterina Mian, Maria R Pelizzo, Enrico De Antoni, Silvio Palermo, Stefania Morrone, Susi Barollo, Angela Nesca, et al.

    The Aurora kinase family members, Aurora-A, -B and -C, are involved in the regulation of mitosis, and alterations in their expression are associated with cell malignant transformation. To date no information on the expression of these proteins in medullary thyroid carcinoma (MTC) are available. We here investigated the expression of the Aurora kinases in human MTC tissues and their potential use as therapeutic targets.